European equities traded in the US as American depositary receipts were treading water late Monday morning, edging 0.04% higher to 1,357.59 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biotech firm Evaxion Biotech (EVAX) and telecommunications company Ericsson (ERIC), which rose 5% and 3.6%, respectively. They were followed by medical device maker EDAP (EDAP) and biopharmaceutical company DBV Technologies (DBVT), which were up 3.1% and 2.8%, respectively.
The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and internet browser company Opera (OPRA), which dropped 3.8% and 3.3%, respectively. They were followed by biopharmaceutical company Grifols (GRFS) and pharmaceutical company Novo Nordisk (NVO), which lost 1.8% and 1.2%, respectively.
From the UK and Ireland, the gainers were led by consumer goods company British American Tobacco (BTI) and biopharmaceutical company Bicycle Therapeutics (BCYC), which increased 3.2% and 2.9%, respectively. They were followed by pharmaceutical companies GSK (GSK) and Silence Therapeutics (SLN), which advanced 2.8% and 2.6%, respectively.
The decliners from the UK and Ireland were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and TC Biopharm (TCBP), which shed 9.7% and 4.3%, respectively. They were followed by biopharmaceutical company NuCana (NCNA) and biotech firm Trinity Biotech (TRIB), which fell 3.5%, each.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。